nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—hypertension	0.301	1	CrCtD
Apraclonidine—ADRA2B—hypertension	0.0901	0.486	CbGaD
Apraclonidine—Lofexidine—Clonidine—hypertension	0.0848	0.409	CrCrCtD
Apraclonidine—Tizanidine—Clonidine—hypertension	0.0613	0.296	CrCrCtD
Apraclonidine—Brimonidine—Clonidine—hypertension	0.0613	0.296	CrCrCtD
Apraclonidine—ADRA1A—hypertension	0.0558	0.301	CbGaD
Apraclonidine—ADRA2A—hypertension	0.0395	0.213	CbGaD
Apraclonidine—ADRA2C—Guanabenz—hypertension	0.0148	0.073	CbGbCtD
Apraclonidine—ADRA2B—Guanabenz—hypertension	0.014	0.0692	CbGbCtD
Apraclonidine—ADRA2B—Guanfacine—hypertension	0.013	0.0644	CbGbCtD
Apraclonidine—ADRA2C—Fenoldopam—hypertension	0.0117	0.0577	CbGbCtD
Apraclonidine—ADRA2B—Fenoldopam—hypertension	0.0111	0.0547	CbGbCtD
Apraclonidine—ADRA2A—Methyldopa—hypertension	0.0107	0.0527	CbGbCtD
Apraclonidine—ADRA2A—Guanabenz—hypertension	0.00975	0.0482	CbGbCtD
Apraclonidine—ADRA2A—Guanfacine—hypertension	0.00906	0.0448	CbGbCtD
Apraclonidine—ADRA2B—Prazosin—hypertension	0.0084	0.0415	CbGbCtD
Apraclonidine—ADRA1A—Terazosin—hypertension	0.00817	0.0404	CbGbCtD
Apraclonidine—ADRA2A—Fenoldopam—hypertension	0.00771	0.0381	CbGbCtD
Apraclonidine—ADRA2C—Carvedilol—hypertension	0.00764	0.0377	CbGbCtD
Apraclonidine—ADRA1A—Fenoldopam—hypertension	0.00739	0.0365	CbGbCtD
Apraclonidine—ADRA2B—Carvedilol—hypertension	0.00725	0.0358	CbGbCtD
Apraclonidine—ADRA2A—Doxazosin—hypertension	0.00711	0.0351	CbGbCtD
Apraclonidine—ADRA1A—Doxazosin—hypertension	0.00682	0.0337	CbGbCtD
Apraclonidine—ADRA2C—Clonidine—hypertension	0.00671	0.0331	CbGbCtD
Apraclonidine—ADRA2B—Clonidine—hypertension	0.00636	0.0314	CbGbCtD
Apraclonidine—ADRA2A—Prazosin—hypertension	0.00584	0.0288	CbGbCtD
Apraclonidine—ADRA1A—Prazosin—hypertension	0.0056	0.0277	CbGbCtD
Apraclonidine—ADRA2A—Carvedilol—hypertension	0.00504	0.0249	CbGbCtD
Apraclonidine—ADRA1A—Carvedilol—hypertension	0.00483	0.0239	CbGbCtD
Apraclonidine—ADRA1A—Nicardipine—hypertension	0.00483	0.0239	CbGbCtD
Apraclonidine—ADRA2A—Clonidine—hypertension	0.00443	0.0219	CbGbCtD
Apraclonidine—ADRA1A—Clonidine—hypertension	0.00424	0.021	CbGbCtD
Apraclonidine—Tizanidine—NISCH—hypertension	0.000474	0.245	CrCbGaD
Apraclonidine—Brimonidine—ADRA2B—hypertension	0.000242	0.125	CrCbGaD
Apraclonidine—Clonidine—NISCH—hypertension	0.000232	0.119	CrCbGaD
Apraclonidine—Tizanidine—ADRA2B—hypertension	0.000221	0.114	CrCbGaD
Apraclonidine—Lofexidine—ADRA2A—hypertension	0.000165	0.0849	CrCbGaD
Apraclonidine—Clonidine—ADRA2B—hypertension	0.000108	0.0558	CrCbGaD
Apraclonidine—Brimonidine—ADRA2A—hypertension	0.000106	0.0547	CrCbGaD
Apraclonidine—Tizanidine—ADRA2A—hypertension	9.7e-05	0.05	CrCbGaD
Apraclonidine—Clonidine—SLC6A2—hypertension	9.5e-05	0.049	CrCbGaD
Apraclonidine—Clonidine—ADRA1A—hypertension	6.69e-05	0.0345	CrCbGaD
Apraclonidine—Clonidine—CYP3A5—hypertension	5.03e-05	0.026	CrCbGaD
Apraclonidine—Clonidine—ADRA2A—hypertension	4.74e-05	0.0244	CrCbGaD
Apraclonidine—Clonidine—CYP1A1—hypertension	3.41e-05	0.0176	CrCbGaD
Apraclonidine—Dermatitis—Diltiazem—hypertension	1.32e-05	0.0002	CcSEcCtD
Apraclonidine—Dermatitis—Indapamide—hypertension	1.32e-05	0.0002	CcSEcCtD
Apraclonidine—Vomiting—Carvedilol—hypertension	1.31e-05	0.0002	CcSEcCtD
Apraclonidine—Feeling abnormal—Perindopril—hypertension	1.31e-05	0.0002	CcSEcCtD
Apraclonidine—Dizziness—Verapamil—hypertension	1.31e-05	0.0002	CcSEcCtD
Apraclonidine—Pain—Betaxolol—hypertension	1.31e-05	0.0002	CcSEcCtD
Apraclonidine—Constipation—Betaxolol—hypertension	1.31e-05	0.0002	CcSEcCtD
Apraclonidine—Feeling abnormal—Irbesartan—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Headache—Indapamide—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Headache—Diltiazem—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Pruritus—Valsartan—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Dry mouth—Ramipril—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Chest pain—Timolol—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Myalgia—Timolol—hypertension	1.31e-05	0.000199	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Perindopril—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Dermatitis—Carvedilol—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Pruritus—Olmesartan—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Vomiting—Doxazosin—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Irbesartan—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Feeling abnormal—Hydrochlorothiazide—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Timolol—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Hypersensitivity—Clonidine—hypertension	1.3e-05	0.000198	CcSEcCtD
Apraclonidine—Abdominal pain—Captopril—hypertension	1.3e-05	0.000197	CcSEcCtD
Apraclonidine—Headache—Carvedilol—hypertension	1.3e-05	0.000197	CcSEcCtD
Apraclonidine—Discomfort—Timolol—hypertension	1.29e-05	0.000197	CcSEcCtD
Apraclonidine—Fatigue—Losartan—hypertension	1.29e-05	0.000196	CcSEcCtD
Apraclonidine—Dermatitis—Doxazosin—hypertension	1.29e-05	0.000196	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Hydrochlorothiazide—hypertension	1.29e-05	0.000196	CcSEcCtD
Apraclonidine—Vomiting—Fosinopril—hypertension	1.28e-05	0.000196	CcSEcCtD
Apraclonidine—Malaise—Lisinopril—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Nausea—Propranolol—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Oedema—Ramipril—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Headache—Doxazosin—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Dry mouth—Timolol—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Constipation—Losartan—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Pain—Losartan—hypertension	1.28e-05	0.000195	CcSEcCtD
Apraclonidine—Syncope—Lisinopril—hypertension	1.28e-05	0.000194	CcSEcCtD
Apraclonidine—Vomiting—Eplerenone—hypertension	1.28e-05	0.000194	CcSEcCtD
Apraclonidine—Feeling abnormal—Furosemide—hypertension	1.28e-05	0.000194	CcSEcCtD
Apraclonidine—Dermatitis—Fosinopril—hypertension	1.27e-05	0.000194	CcSEcCtD
Apraclonidine—Vomiting—Nifedipine—hypertension	1.27e-05	0.000193	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Furosemide—hypertension	1.27e-05	0.000193	CcSEcCtD
Apraclonidine—Headache—Fosinopril—hypertension	1.27e-05	0.000193	CcSEcCtD
Apraclonidine—Hypersensitivity—Trandolapril—hypertension	1.27e-05	0.000193	CcSEcCtD
Apraclonidine—Dermatitis—Eplerenone—hypertension	1.27e-05	0.000193	CcSEcCtD
Apraclonidine—Diarrhoea—Valsartan—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Asthenia—Clonidine—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Feeling abnormal—Betaxolol—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Vomiting—Verapamil—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Hypersensitivity—Enalapril—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Abdominal pain—Perindopril—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Palpitations—Lisinopril—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Diarrhoea—Olmesartan—hypertension	1.26e-05	0.000192	CcSEcCtD
Apraclonidine—Headache—Eplerenone—hypertension	1.26e-05	0.000191	CcSEcCtD
Apraclonidine—Nervous system disorder—Ramipril—hypertension	1.26e-05	0.000191	CcSEcCtD
Apraclonidine—Dermatitis—Nifedipine—hypertension	1.26e-05	0.000191	CcSEcCtD
Apraclonidine—Abdominal pain—Irbesartan—hypertension	1.26e-05	0.000191	CcSEcCtD
Apraclonidine—Oedema—Timolol—hypertension	1.25e-05	0.000191	CcSEcCtD
Apraclonidine—Dermatitis—Verapamil—hypertension	1.25e-05	0.00019	CcSEcCtD
Apraclonidine—Headache—Nifedipine—hypertension	1.25e-05	0.00019	CcSEcCtD
Apraclonidine—Pruritus—Clonidine—hypertension	1.25e-05	0.00019	CcSEcCtD
Apraclonidine—Abdominal pain—Hydrochlorothiazide—hypertension	1.25e-05	0.00019	CcSEcCtD
Apraclonidine—Skin disorder—Ramipril—hypertension	1.24e-05	0.000189	CcSEcCtD
Apraclonidine—Infection—Timolol—hypertension	1.24e-05	0.000189	CcSEcCtD
Apraclonidine—Headache—Verapamil—hypertension	1.24e-05	0.000189	CcSEcCtD
Apraclonidine—Hypersensitivity—Telmisartan—hypertension	1.24e-05	0.000189	CcSEcCtD
Apraclonidine—Nausea—Indapamide—hypertension	1.24e-05	0.000189	CcSEcCtD
Apraclonidine—Nausea—Diltiazem—hypertension	1.24e-05	0.000189	CcSEcCtD
Apraclonidine—Asthenia—Trandolapril—hypertension	1.23e-05	0.000188	CcSEcCtD
Apraclonidine—Feeling abnormal—Losartan—hypertension	1.23e-05	0.000187	CcSEcCtD
Apraclonidine—Nervous system disorder—Timolol—hypertension	1.23e-05	0.000187	CcSEcCtD
Apraclonidine—Nausea—Carvedilol—hypertension	1.23e-05	0.000187	CcSEcCtD
Apraclonidine—Asthenia—Enalapril—hypertension	1.23e-05	0.000187	CcSEcCtD
Apraclonidine—Abdominal pain—Furosemide—hypertension	1.22e-05	0.000186	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Losartan—hypertension	1.22e-05	0.000186	CcSEcCtD
Apraclonidine—Dizziness—Valsartan—hypertension	1.22e-05	0.000186	CcSEcCtD
Apraclonidine—Skin disorder—Timolol—hypertension	1.22e-05	0.000185	CcSEcCtD
Apraclonidine—Dizziness—Olmesartan—hypertension	1.22e-05	0.000185	CcSEcCtD
Apraclonidine—Pruritus—Trandolapril—hypertension	1.22e-05	0.000185	CcSEcCtD
Apraclonidine—Nausea—Doxazosin—hypertension	1.21e-05	0.000185	CcSEcCtD
Apraclonidine—Myalgia—Lisinopril—hypertension	1.21e-05	0.000185	CcSEcCtD
Apraclonidine—Chest pain—Lisinopril—hypertension	1.21e-05	0.000185	CcSEcCtD
Apraclonidine—Asthenia—Telmisartan—hypertension	1.21e-05	0.000184	CcSEcCtD
Apraclonidine—Pruritus—Enalapril—hypertension	1.21e-05	0.000184	CcSEcCtD
Apraclonidine—Diarrhoea—Clonidine—hypertension	1.21e-05	0.000183	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—hypertension	1.2e-05	0.000183	CcSEcCtD
Apraclonidine—Nausea—Fosinopril—hypertension	1.2e-05	0.000183	CcSEcCtD
Apraclonidine—Discomfort—Lisinopril—hypertension	1.2e-05	0.000182	CcSEcCtD
Apraclonidine—Pruritus—Telmisartan—hypertension	1.19e-05	0.000182	CcSEcCtD
Apraclonidine—Nausea—Eplerenone—hypertension	1.19e-05	0.000182	CcSEcCtD
Apraclonidine—Dry mouth—Lisinopril—hypertension	1.19e-05	0.00018	CcSEcCtD
Apraclonidine—Nausea—Nifedipine—hypertension	1.18e-05	0.00018	CcSEcCtD
Apraclonidine—Abdominal pain—Losartan—hypertension	1.18e-05	0.00018	CcSEcCtD
Apraclonidine—Nausea—Verapamil—hypertension	1.18e-05	0.000179	CcSEcCtD
Apraclonidine—Asthenia—Captopril—hypertension	1.18e-05	0.000179	CcSEcCtD
Apraclonidine—Diarrhoea—Trandolapril—hypertension	1.18e-05	0.000179	CcSEcCtD
Apraclonidine—Vomiting—Valsartan—hypertension	1.17e-05	0.000179	CcSEcCtD
Apraclonidine—Diarrhoea—Enalapril—hypertension	1.17e-05	0.000178	CcSEcCtD
Apraclonidine—Hypersensitivity—Irbesartan—hypertension	1.17e-05	0.000178	CcSEcCtD
Apraclonidine—Vomiting—Olmesartan—hypertension	1.17e-05	0.000178	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Ramipril—hypertension	1.17e-05	0.000178	CcSEcCtD
Apraclonidine—Dizziness—Clonidine—hypertension	1.16e-05	0.000177	CcSEcCtD
Apraclonidine—Dermatitis—Valsartan—hypertension	1.16e-05	0.000177	CcSEcCtD
Apraclonidine—Oedema—Lisinopril—hypertension	1.16e-05	0.000177	CcSEcCtD
Apraclonidine—Pruritus—Captopril—hypertension	1.16e-05	0.000177	CcSEcCtD
Apraclonidine—Hypersensitivity—Hydrochlorothiazide—hypertension	1.16e-05	0.000177	CcSEcCtD
Apraclonidine—Insomnia—Ramipril—hypertension	1.16e-05	0.000176	CcSEcCtD
Apraclonidine—Dermatitis—Olmesartan—hypertension	1.16e-05	0.000176	CcSEcCtD
Apraclonidine—Headache—Valsartan—hypertension	1.16e-05	0.000176	CcSEcCtD
Apraclonidine—Diarrhoea—Telmisartan—hypertension	1.15e-05	0.000176	CcSEcCtD
Apraclonidine—Infection—Lisinopril—hypertension	1.15e-05	0.000176	CcSEcCtD
Apraclonidine—Headache—Olmesartan—hypertension	1.15e-05	0.000175	CcSEcCtD
Apraclonidine—Paraesthesia—Ramipril—hypertension	1.15e-05	0.000175	CcSEcCtD
Apraclonidine—Asthenia—Perindopril—hypertension	1.14e-05	0.000174	CcSEcCtD
Apraclonidine—Dyspnoea—Ramipril—hypertension	1.14e-05	0.000174	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Timolol—hypertension	1.14e-05	0.000174	CcSEcCtD
Apraclonidine—Hypersensitivity—Furosemide—hypertension	1.14e-05	0.000174	CcSEcCtD
Apraclonidine—Asthenia—Irbesartan—hypertension	1.14e-05	0.000173	CcSEcCtD
Apraclonidine—Somnolence—Ramipril—hypertension	1.14e-05	0.000173	CcSEcCtD
Apraclonidine—Dizziness—Trandolapril—hypertension	1.14e-05	0.000173	CcSEcCtD
Apraclonidine—Insomnia—Timolol—hypertension	1.13e-05	0.000172	CcSEcCtD
Apraclonidine—Dizziness—Enalapril—hypertension	1.13e-05	0.000172	CcSEcCtD
Apraclonidine—Asthenia—Hydrochlorothiazide—hypertension	1.13e-05	0.000172	CcSEcCtD
Apraclonidine—Hypersensitivity—Betaxolol—hypertension	1.13e-05	0.000172	CcSEcCtD
Apraclonidine—Skin disorder—Lisinopril—hypertension	1.13e-05	0.000172	CcSEcCtD
Apraclonidine—Pruritus—Perindopril—hypertension	1.13e-05	0.000172	CcSEcCtD
Apraclonidine—Paraesthesia—Timolol—hypertension	1.12e-05	0.000171	CcSEcCtD
Apraclonidine—Pruritus—Irbesartan—hypertension	1.12e-05	0.000171	CcSEcCtD
Apraclonidine—Diarrhoea—Captopril—hypertension	1.12e-05	0.000171	CcSEcCtD
Apraclonidine—Vomiting—Clonidine—hypertension	1.12e-05	0.00017	CcSEcCtD
Apraclonidine—Dyspnoea—Timolol—hypertension	1.12e-05	0.00017	CcSEcCtD
Apraclonidine—Dizziness—Telmisartan—hypertension	1.12e-05	0.00017	CcSEcCtD
Apraclonidine—Pruritus—Hydrochlorothiazide—hypertension	1.11e-05	0.00017	CcSEcCtD
Apraclonidine—Somnolence—Timolol—hypertension	1.11e-05	0.00017	CcSEcCtD
Apraclonidine—Asthenia—Furosemide—hypertension	1.11e-05	0.000169	CcSEcCtD
Apraclonidine—Dermatitis—Clonidine—hypertension	1.11e-05	0.000169	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ramipril—hypertension	1.11e-05	0.000168	CcSEcCtD
Apraclonidine—Fatigue—Ramipril—hypertension	1.1e-05	0.000168	CcSEcCtD
Apraclonidine—Headache—Clonidine—hypertension	1.1e-05	0.000168	CcSEcCtD
Apraclonidine—Hypersensitivity—Losartan—hypertension	1.1e-05	0.000168	CcSEcCtD
Apraclonidine—Asthenia—Betaxolol—hypertension	1.1e-05	0.000167	CcSEcCtD
Apraclonidine—Nausea—Valsartan—hypertension	1.1e-05	0.000167	CcSEcCtD
Apraclonidine—Pruritus—Furosemide—hypertension	1.1e-05	0.000167	CcSEcCtD
Apraclonidine—Constipation—Ramipril—hypertension	1.1e-05	0.000167	CcSEcCtD
Apraclonidine—Nausea—Olmesartan—hypertension	1.09e-05	0.000166	CcSEcCtD
Apraclonidine—Vomiting—Trandolapril—hypertension	1.09e-05	0.000166	CcSEcCtD
Apraclonidine—Diarrhoea—Perindopril—hypertension	1.09e-05	0.000166	CcSEcCtD
Apraclonidine—Vomiting—Enalapril—hypertension	1.09e-05	0.000166	CcSEcCtD
Apraclonidine—Diarrhoea—Irbesartan—hypertension	1.09e-05	0.000165	CcSEcCtD
Apraclonidine—Dizziness—Captopril—hypertension	1.09e-05	0.000165	CcSEcCtD
Apraclonidine—Pruritus—Betaxolol—hypertension	1.08e-05	0.000165	CcSEcCtD
Apraclonidine—Dermatitis—Trandolapril—hypertension	1.08e-05	0.000165	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Timolol—hypertension	1.08e-05	0.000165	CcSEcCtD
Apraclonidine—Fatigue—Timolol—hypertension	1.08e-05	0.000164	CcSEcCtD
Apraclonidine—Dermatitis—Enalapril—hypertension	1.08e-05	0.000164	CcSEcCtD
Apraclonidine—Diarrhoea—Hydrochlorothiazide—hypertension	1.08e-05	0.000164	CcSEcCtD
Apraclonidine—Headache—Trandolapril—hypertension	1.08e-05	0.000164	CcSEcCtD
Apraclonidine—Vomiting—Telmisartan—hypertension	1.07e-05	0.000163	CcSEcCtD
Apraclonidine—Asthenia—Losartan—hypertension	1.07e-05	0.000163	CcSEcCtD
Apraclonidine—Headache—Enalapril—hypertension	1.07e-05	0.000163	CcSEcCtD
Apraclonidine—Pain—Timolol—hypertension	1.07e-05	0.000163	CcSEcCtD
Apraclonidine—Dermatitis—Telmisartan—hypertension	1.06e-05	0.000162	CcSEcCtD
Apraclonidine—Diarrhoea—Furosemide—hypertension	1.06e-05	0.000161	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Lisinopril—hypertension	1.06e-05	0.000161	CcSEcCtD
Apraclonidine—Pruritus—Losartan—hypertension	1.06e-05	0.000161	CcSEcCtD
Apraclonidine—Headache—Telmisartan—hypertension	1.06e-05	0.000161	CcSEcCtD
Apraclonidine—Feeling abnormal—Ramipril—hypertension	1.06e-05	0.000161	CcSEcCtD
Apraclonidine—Dizziness—Perindopril—hypertension	1.05e-05	0.00016	CcSEcCtD
Apraclonidine—Insomnia—Lisinopril—hypertension	1.05e-05	0.00016	CcSEcCtD
Apraclonidine—Dizziness—Irbesartan—hypertension	1.05e-05	0.00016	CcSEcCtD
Apraclonidine—Diarrhoea—Betaxolol—hypertension	1.05e-05	0.00016	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ramipril—hypertension	1.05e-05	0.000159	CcSEcCtD
Apraclonidine—Nausea—Clonidine—hypertension	1.05e-05	0.000159	CcSEcCtD
Apraclonidine—Paraesthesia—Lisinopril—hypertension	1.04e-05	0.000159	CcSEcCtD
Apraclonidine—Vomiting—Captopril—hypertension	1.04e-05	0.000159	CcSEcCtD
Apraclonidine—Dizziness—Hydrochlorothiazide—hypertension	1.04e-05	0.000159	CcSEcCtD
Apraclonidine—Dyspnoea—Lisinopril—hypertension	1.04e-05	0.000158	CcSEcCtD
Apraclonidine—Dermatitis—Captopril—hypertension	1.03e-05	0.000157	CcSEcCtD
Apraclonidine—Somnolence—Lisinopril—hypertension	1.03e-05	0.000157	CcSEcCtD
Apraclonidine—Feeling abnormal—Timolol—hypertension	1.03e-05	0.000157	CcSEcCtD
Apraclonidine—Headache—Captopril—hypertension	1.03e-05	0.000156	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Timolol—hypertension	1.02e-05	0.000156	CcSEcCtD
Apraclonidine—Dizziness—Furosemide—hypertension	1.02e-05	0.000156	CcSEcCtD
Apraclonidine—Diarrhoea—Losartan—hypertension	1.02e-05	0.000156	CcSEcCtD
Apraclonidine—Nausea—Trandolapril—hypertension	1.02e-05	0.000155	CcSEcCtD
Apraclonidine—Nausea—Enalapril—hypertension	1.02e-05	0.000155	CcSEcCtD
Apraclonidine—Dizziness—Betaxolol—hypertension	1.01e-05	0.000154	CcSEcCtD
Apraclonidine—Vomiting—Perindopril—hypertension	1.01e-05	0.000154	CcSEcCtD
Apraclonidine—Abdominal pain—Ramipril—hypertension	1.01e-05	0.000154	CcSEcCtD
Apraclonidine—Vomiting—Irbesartan—hypertension	1.01e-05	0.000154	CcSEcCtD
Apraclonidine—Dermatitis—Perindopril—hypertension	1e-05	0.000153	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Lisinopril—hypertension	1e-05	0.000153	CcSEcCtD
Apraclonidine—Nausea—Telmisartan—hypertension	1e-05	0.000153	CcSEcCtD
Apraclonidine—Fatigue—Lisinopril—hypertension	1e-05	0.000153	CcSEcCtD
Apraclonidine—Vomiting—Hydrochlorothiazide—hypertension	1e-05	0.000152	CcSEcCtD
Apraclonidine—Dermatitis—Irbesartan—hypertension	1e-05	0.000152	CcSEcCtD
Apraclonidine—Headache—Perindopril—hypertension	9.98e-06	0.000152	CcSEcCtD
Apraclonidine—Headache—Irbesartan—hypertension	9.95e-06	0.000151	CcSEcCtD
Apraclonidine—Constipation—Lisinopril—hypertension	9.94e-06	0.000151	CcSEcCtD
Apraclonidine—Pain—Lisinopril—hypertension	9.94e-06	0.000151	CcSEcCtD
Apraclonidine—Dermatitis—Hydrochlorothiazide—hypertension	9.92e-06	0.000151	CcSEcCtD
Apraclonidine—Abdominal pain—Timolol—hypertension	9.9e-06	0.000151	CcSEcCtD
Apraclonidine—Dizziness—Losartan—hypertension	9.88e-06	0.00015	CcSEcCtD
Apraclonidine—Headache—Hydrochlorothiazide—hypertension	9.87e-06	0.00015	CcSEcCtD
Apraclonidine—Vomiting—Furosemide—hypertension	9.85e-06	0.00015	CcSEcCtD
Apraclonidine—Dermatitis—Furosemide—hypertension	9.76e-06	0.000149	CcSEcCtD
Apraclonidine—Vomiting—Betaxolol—hypertension	9.75e-06	0.000148	CcSEcCtD
Apraclonidine—Nausea—Captopril—hypertension	9.75e-06	0.000148	CcSEcCtD
Apraclonidine—Headache—Furosemide—hypertension	9.7e-06	0.000148	CcSEcCtD
Apraclonidine—Dermatitis—Betaxolol—hypertension	9.66e-06	0.000147	CcSEcCtD
Apraclonidine—Headache—Betaxolol—hypertension	9.61e-06	0.000146	CcSEcCtD
Apraclonidine—Feeling abnormal—Lisinopril—hypertension	9.58e-06	0.000146	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Lisinopril—hypertension	9.5e-06	0.000145	CcSEcCtD
Apraclonidine—Vomiting—Losartan—hypertension	9.5e-06	0.000145	CcSEcCtD
Apraclonidine—Nausea—Perindopril—hypertension	9.46e-06	0.000144	CcSEcCtD
Apraclonidine—Hypersensitivity—Ramipril—hypertension	9.44e-06	0.000144	CcSEcCtD
Apraclonidine—Nausea—Irbesartan—hypertension	9.43e-06	0.000144	CcSEcCtD
Apraclonidine—Dermatitis—Losartan—hypertension	9.41e-06	0.000143	CcSEcCtD
Apraclonidine—Headache—Losartan—hypertension	9.36e-06	0.000143	CcSEcCtD
Apraclonidine—Nausea—Hydrochlorothiazide—hypertension	9.35e-06	0.000142	CcSEcCtD
Apraclonidine—Hypersensitivity—Timolol—hypertension	9.23e-06	0.00014	CcSEcCtD
Apraclonidine—Nausea—Furosemide—hypertension	9.2e-06	0.00014	CcSEcCtD
Apraclonidine—Asthenia—Ramipril—hypertension	9.19e-06	0.00014	CcSEcCtD
Apraclonidine—Abdominal pain—Lisinopril—hypertension	9.19e-06	0.00014	CcSEcCtD
Apraclonidine—Nausea—Betaxolol—hypertension	9.11e-06	0.000139	CcSEcCtD
Apraclonidine—Pruritus—Ramipril—hypertension	9.07e-06	0.000138	CcSEcCtD
Apraclonidine—Asthenia—Timolol—hypertension	8.99e-06	0.000137	CcSEcCtD
Apraclonidine—Nausea—Losartan—hypertension	8.88e-06	0.000135	CcSEcCtD
Apraclonidine—Pruritus—Timolol—hypertension	8.86e-06	0.000135	CcSEcCtD
Apraclonidine—Diarrhoea—Ramipril—hypertension	8.77e-06	0.000133	CcSEcCtD
Apraclonidine—Diarrhoea—Timolol—hypertension	8.57e-06	0.00013	CcSEcCtD
Apraclonidine—Hypersensitivity—Lisinopril—hypertension	8.56e-06	0.00013	CcSEcCtD
Apraclonidine—Dizziness—Ramipril—hypertension	8.47e-06	0.000129	CcSEcCtD
Apraclonidine—Asthenia—Lisinopril—hypertension	8.34e-06	0.000127	CcSEcCtD
Apraclonidine—Dizziness—Timolol—hypertension	8.28e-06	0.000126	CcSEcCtD
Apraclonidine—Pruritus—Lisinopril—hypertension	8.22e-06	0.000125	CcSEcCtD
Apraclonidine—Vomiting—Ramipril—hypertension	8.15e-06	0.000124	CcSEcCtD
Apraclonidine—Dermatitis—Ramipril—hypertension	8.07e-06	0.000123	CcSEcCtD
Apraclonidine—Headache—Ramipril—hypertension	8.03e-06	0.000122	CcSEcCtD
Apraclonidine—Vomiting—Timolol—hypertension	7.96e-06	0.000121	CcSEcCtD
Apraclonidine—Diarrhoea—Lisinopril—hypertension	7.95e-06	0.000121	CcSEcCtD
Apraclonidine—Dermatitis—Timolol—hypertension	7.89e-06	0.00012	CcSEcCtD
Apraclonidine—Headache—Timolol—hypertension	7.85e-06	0.000119	CcSEcCtD
Apraclonidine—Dizziness—Lisinopril—hypertension	7.68e-06	0.000117	CcSEcCtD
Apraclonidine—Nausea—Ramipril—hypertension	7.61e-06	0.000116	CcSEcCtD
Apraclonidine—Nausea—Timolol—hypertension	7.44e-06	0.000113	CcSEcCtD
Apraclonidine—Vomiting—Lisinopril—hypertension	7.39e-06	0.000112	CcSEcCtD
Apraclonidine—Dermatitis—Lisinopril—hypertension	7.32e-06	0.000111	CcSEcCtD
Apraclonidine—Headache—Lisinopril—hypertension	7.28e-06	0.000111	CcSEcCtD
Apraclonidine—Nausea—Lisinopril—hypertension	6.9e-06	0.000105	CcSEcCtD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—hypertension	1.42e-06	3.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—hypertension	1.41e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EDN1—hypertension	1.41e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CALM1—hypertension	1.41e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFBR2—hypertension	1.41e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—C3—hypertension	1.41e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—hypertension	1.4e-06	3.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—hypertension	1.4e-06	3.92e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL5—hypertension	1.4e-06	3.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNB3—hypertension	1.4e-06	3.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CAV1—hypertension	1.39e-06	3.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—hypertension	1.39e-06	3.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AVP—hypertension	1.38e-06	3.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KDR—hypertension	1.38e-06	3.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PDGFB—hypertension	1.37e-06	3.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—hypertension	1.37e-06	3.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—hypertension	1.37e-06	3.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—hypertension	1.37e-06	3.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RHOA—hypertension	1.37e-06	3.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGFR1—hypertension	1.36e-06	3.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNAS—hypertension	1.36e-06	3.8e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—H2AFX—hypertension	1.36e-06	3.8e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RPS6KB1—hypertension	1.36e-06	3.79e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDGFRB—hypertension	1.36e-06	3.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3R1—hypertension	1.35e-06	3.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—hypertension	1.35e-06	3.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—hypertension	1.34e-06	3.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARA—hypertension	1.34e-06	3.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—hypertension	1.34e-06	3.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADCY5—hypertension	1.34e-06	3.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—hypertension	1.34e-06	3.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—hypertension	1.33e-06	3.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOB—hypertension	1.33e-06	3.72e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCG—hypertension	1.33e-06	3.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTK2—hypertension	1.33e-06	3.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FN1—hypertension	1.32e-06	3.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCB—hypertension	1.32e-06	3.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—F2—hypertension	1.32e-06	3.7e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ITGB3—hypertension	1.32e-06	3.69e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCA—hypertension	1.32e-06	3.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—hypertension	1.32e-06	3.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CALM1—hypertension	1.32e-06	3.68e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—hypertension	1.31e-06	3.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—hypertension	1.31e-06	3.67e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—YWHAZ—hypertension	1.31e-06	3.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDN1—hypertension	1.31e-06	3.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—hypertension	1.3e-06	3.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL5—hypertension	1.3e-06	3.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CAV1—hypertension	1.3e-06	3.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—hypertension	1.3e-06	3.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH1—hypertension	1.3e-06	3.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NGF—hypertension	1.3e-06	3.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPP1—hypertension	1.3e-06	3.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—hypertension	1.29e-06	3.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—hypertension	1.28e-06	3.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—hypertension	1.28e-06	3.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CALM1—hypertension	1.28e-06	3.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—hypertension	1.27e-06	3.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—hypertension	1.27e-06	3.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—hypertension	1.26e-06	3.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—H2AFX—hypertension	1.26e-06	3.53e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCD—hypertension	1.26e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCR5—hypertension	1.26e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFRB—hypertension	1.26e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RPS6KB1—hypertension	1.26e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—hypertension	1.26e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADCY5—hypertension	1.24e-06	3.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—F2—hypertension	1.24e-06	3.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FN1—hypertension	1.24e-06	3.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCB—hypertension	1.24e-06	3.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCG—hypertension	1.24e-06	3.45e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—hypertension	1.23e-06	3.45e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—C3—hypertension	1.23e-06	3.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—hypertension	1.23e-06	3.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ITGB3—hypertension	1.23e-06	3.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCA—hypertension	1.23e-06	3.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—YWHAZ—hypertension	1.22e-06	3.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—hypertension	1.21e-06	3.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—hypertension	1.21e-06	3.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NGF—hypertension	1.2e-06	3.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—hypertension	1.2e-06	3.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—hypertension	1.2e-06	3.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDGFB—hypertension	1.2e-06	3.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—hypertension	1.2e-06	3.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR1—hypertension	1.19e-06	3.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—hypertension	1.18e-06	3.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—hypertension	1.18e-06	3.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3R1—hypertension	1.18e-06	3.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—hypertension	1.17e-06	3.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCR5—hypertension	1.17e-06	3.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCD—hypertension	1.17e-06	3.27e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—hypertension	1.17e-06	3.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—hypertension	1.16e-06	3.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT2—hypertension	1.16e-06	3.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—hypertension	1.15e-06	3.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CALM1—hypertension	1.15e-06	3.22e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—hypertension	1.15e-06	3.2e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—hypertension	1.15e-06	3.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—hypertension	1.15e-06	3.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—C3—hypertension	1.14e-06	3.2e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—hypertension	1.14e-06	3.17e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—hypertension	1.13e-06	3.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—hypertension	1.13e-06	3.15e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—hypertension	1.12e-06	3.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—hypertension	1.12e-06	3.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFB—hypertension	1.11e-06	3.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—hypertension	1.11e-06	3.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR1—hypertension	1.11e-06	3.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—hypertension	1.1e-06	3.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—hypertension	1.1e-06	3.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—hypertension	1.09e-06	3.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—hypertension	1.09e-06	3.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—hypertension	1.09e-06	3.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—hypertension	1.09e-06	3.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—hypertension	1.08e-06	3.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT2—hypertension	1.08e-06	3.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—hypertension	1.08e-06	3.02e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCB—hypertension	1.08e-06	3.02e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—F2—hypertension	1.08e-06	3.02e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FN1—hypertension	1.08e-06	3.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—hypertension	1.08e-06	3.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—hypertension	1.07e-06	3e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CALM1—hypertension	1.07e-06	2.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF2—hypertension	1.07e-06	2.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—hypertension	1.07e-06	2.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—hypertension	1.07e-06	2.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RHOA—hypertension	1.06e-06	2.97e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—hypertension	1.06e-06	2.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—hypertension	1.06e-06	2.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—hypertension	1.05e-06	2.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3R1—hypertension	1.05e-06	2.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—hypertension	1.05e-06	2.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—hypertension	1.04e-06	2.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—hypertension	1.03e-06	2.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCB—hypertension	1e-06	2.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FN1—hypertension	1e-06	2.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—F2—hypertension	1e-06	2.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—hypertension	9.98e-07	2.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF2—hypertension	9.96e-07	2.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RHOA—hypertension	9.93e-07	2.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RELA—hypertension	9.9e-07	2.77e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—hypertension	9.85e-07	2.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—hypertension	9.83e-07	2.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—hypertension	9.83e-07	2.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3R1—hypertension	9.83e-07	2.75e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—hypertension	9.79e-07	2.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—hypertension	9.71e-07	2.71e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—hypertension	9.64e-07	2.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—hypertension	9.54e-07	2.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3R1—hypertension	9.54e-07	2.67e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—hypertension	9.47e-07	2.65e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT2—hypertension	9.47e-07	2.65e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—hypertension	9.43e-07	2.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—hypertension	9.37e-07	2.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—hypertension	9.33e-07	2.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RELA—hypertension	9.25e-07	2.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—hypertension	9.15e-07	2.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—hypertension	9.1e-07	2.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—hypertension	9.07e-07	2.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—hypertension	9.01e-07	2.52e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—hypertension	9e-07	2.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—hypertension	8.95e-07	2.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—EP300—hypertension	8.94e-07	2.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—hypertension	8.87e-07	2.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—hypertension	8.8e-07	2.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT2—hypertension	8.8e-07	2.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—hypertension	8.76e-07	2.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—hypertension	8.73e-07	2.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—hypertension	8.72e-07	2.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF2—hypertension	8.71e-07	2.43e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RHOA—hypertension	8.68e-07	2.43e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3R1—hypertension	8.59e-07	2.4e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—hypertension	8.59e-07	2.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—hypertension	8.44e-07	2.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—hypertension	8.42e-07	2.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—hypertension	8.41e-07	2.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—hypertension	8.39e-07	2.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—hypertension	8.36e-07	2.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—hypertension	8.29e-07	2.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—hypertension	8.21e-07	2.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—hypertension	8.18e-07	2.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF2—hypertension	8.09e-07	2.26e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RELA—hypertension	8.08e-07	2.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RHOA—hypertension	8.06e-07	2.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EP300—hypertension	8e-07	2.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3R1—hypertension	7.98e-07	2.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—hypertension	7.98e-07	2.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—hypertension	7.93e-07	2.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—hypertension	7.88e-07	2.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—hypertension	7.85e-07	2.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—hypertension	7.84e-07	2.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—hypertension	7.78e-07	2.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—hypertension	7.67e-07	2.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—hypertension	7.65e-07	2.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—hypertension	7.62e-07	2.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—hypertension	7.61e-07	2.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—hypertension	7.58e-07	2.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RELA—hypertension	7.51e-07	2.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EP300—hypertension	7.47e-07	2.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—hypertension	7.37e-07	2.06e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—hypertension	7.36e-07	2.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—hypertension	7.27e-07	2.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—EP300—hypertension	7.26e-07	2.03e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—hypertension	7.24e-07	2.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—hypertension	7.08e-07	1.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—hypertension	7.08e-07	1.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—hypertension	6.97e-07	1.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—hypertension	6.96e-07	1.94e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—hypertension	6.89e-07	1.93e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—hypertension	6.87e-07	1.92e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—hypertension	6.85e-07	1.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—hypertension	6.84e-07	1.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—hypertension	6.82e-07	1.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—hypertension	6.73e-07	1.88e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—hypertension	6.7e-07	1.87e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—hypertension	6.68e-07	1.87e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EP300—hypertension	6.53e-07	1.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—hypertension	6.51e-07	1.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—hypertension	6.5e-07	1.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—hypertension	6.4e-07	1.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—hypertension	6.38e-07	1.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—hypertension	6.37e-07	1.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—hypertension	6.37e-07	1.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—hypertension	6.35e-07	1.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—hypertension	6.23e-07	1.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—hypertension	6.21e-07	1.74e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—hypertension	6.19e-07	1.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EP300—hypertension	6.07e-07	1.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—hypertension	5.9e-07	1.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—hypertension	5.75e-07	1.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—hypertension	5.73e-07	1.6e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—hypertension	5.69e-07	1.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—hypertension	5.68e-07	1.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—hypertension	5.57e-07	1.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—hypertension	5.4e-07	1.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—hypertension	5.35e-07	1.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—hypertension	5.29e-07	1.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—hypertension	5.28e-07	1.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—hypertension	5.24e-07	1.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—hypertension	5.17e-07	1.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—hypertension	4.9e-07	1.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—hypertension	4.84e-07	1.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—hypertension	4.68e-07	1.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—hypertension	4.52e-07	1.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—hypertension	4.39e-07	1.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—hypertension	4.34e-07	1.21e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—hypertension	4.28e-07	1.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—hypertension	3.98e-07	1.11e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—hypertension	3.95e-07	1.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—hypertension	3.67e-07	1.03e-05	CbGpPWpGaD
